Rigo and colleagues showed that combining CPi with temporary CD4 depletion by anti-CD4 monoclonal antibody (mAb) treatment caused a very potent CD8 T cell dependent response causing significantly longer tumor-free survival, complete tumor regression, and durable anti-NBL immunity in vivo [111]. Here, CD8A is linked to neoplasm.